NewsFeed Voices Science Insight Innovation
November, 2025
November 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
Wolfgang Miesbach – ASH 2025: What’s Coming in Bleeding and Thrombosis?
Wolfgang Miesbach/LinkedIn
Nov 13, 2025, 01:08

Wolfgang Miesbach – ASH 2025: What’s Coming in Bleeding and Thrombosis?

Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn:

”By The Numbers
– 8,200 abstracts (record-breaking)
– 650-980 hemostasis-focused presentations across 8 categories
– 50 Sanofi abstracts | 46 Roche | 25+ Takeda contributions
– 6 late-breaking abstracts drop December 1 + 6 plenary abstracts

Haemophilia: Game-Changing Therapies
– Next-Gen Bispecific Antibodies
– Gene Therapy Updates
– RNA Silencing

Platelet Disorders: ITP Innovation
Rilzabrutinib (WAYRILZ) – First BTK inhibitor for ITP
– 65% platelet response vs 33% placebo
– 23% durable response vs 0% placebo
– Reduced bleeding + improved quality of life
– Plus: New data on rilzabrutinib in warm autoimmune hemolytic anemia (wAIHA) and sickle cell disease

Thrombosis: A Major Shift
NEW 2025 ASH/ISTH Pediatric VTE Guidelines
DOACs (rivaroxaban, dabigatran) now preferred over standard care (LMWH/warfarin) for kids with VTE. Oral anticoagulation changing the game.
Novel Thrombolytic Therapy
TargED Biopharmaceuticals’ TGD001 – first-in-human data on VWF-targeting thrombolytic for stroke, PE, and thrombotic thrombocytopenic purpura

Von Willebrand Disease
– VONVENDI Phase 3 pediatric data (supported Sept 2025 FDA approval)
– VGA039 – novel Protein S-targeting antibody with Phase 1/2 multidose results”

ASH 2025

Stay updated with Hemostasis Today.

American Society of Hematology Anticoagulation ASH 2025 bleeding bleeding disorders Frankfurt University Hospital haemophilia Health Hematology Hemostasis Hemostasis Today Immune thrombocytopenia ITP Medicine Platelet disorders thrombosis Von Willebrand Disease Wolfgang Miesbach
NewsFeed